Pharmaceutical compositions directed to Erb-B1 receptors

Details Pharmaceutical compositions directed to Erb-B1 receptors Pharmaceutical compositions directed to Erb-B1 receptors

2003-10-09

2009-12-29

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S143100, C435S810000, C530S387100, C530S387300, C530S388220, C530S351000

Reexamination Certificate

active

07638125

ABSTRACT:
The invention relates to pharmaceutical compositions comprising different molecules, preferably monoclonal antibodies, each comprising epitopes that bind simultaneously to different sites within the same ErbB receptor domain, preferably the ErbB1 receptor domain. The preferred antibodies according to this invention are MAb 425 and MAb 225 each in its murine, chimeric and humanized version. The invention relates to the use and methods for an improved treatment of preferably tumors by means of said compositions.

REFERENCES:
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5705157 (1998-01-01), Greene
patent: 5861449 (1999-01-01), Akitomo et al.
patent: 6217866 (2001-04-01), Schlessinger et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 0 667 165 (1995-08-01), None
patent: 94 00136 (1994-01-01), None
patent: 02 055106 (2002-07-01), None
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
McInnes et al, Biopoly 43: 339-366, 1997.
Dermer et al, Bio/Technology 12: 320, 1994.
Gura et al, Science 278: 1041-1042, Nov 1997.
Modjtahedi et al, Cell Biophys 22(1-3): 129-146, Jan.-Jun. 1993.
Ye et al, Oncogene 18: 731-738, 1999.
Fan et al, Cancer Research 53: 4322-4328, 1993.
Ciardiello et al, Clinical Cancer Research 5: 909-916, Apr. 1999.
Gill et al, J Biol Chemistry 259(12): 7755-7760, 1984.
Mendelsohn et al, Oncogene 19: 6550,6565, 2000.
Ye D et al: “Augmentation of a Humanized Anti-HER2 MAb 4D5 Induced Growth Inhibition by a Human-Mouse Chimeric Anti-EGF Receeptor MAb C225” Oncogene, Basinstoke, Hants, GB, vol. 18, No. 3, Jan. 21, 1999, pp. 731-738.
Kasprzyk P G et al: “Terhapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-ErbB-2 Monoclonal Antibodies” Cancer Research, Amercian Association for Cancer Research, Baltimore, MD, US, vol. 52, May 15, 1992, pp. 2771-2776.
Dechant et al. “Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies.”Cancer Research68, 4998-5003, Jul. 1, 2008.

Affiliated with

Also associated with

Rating

Pharmaceutical compositions directed to Erb-B1 receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions directed to Erb-B1 receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions directed to Erb-B1 receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4086920